Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8

Benzinga · 1d ago
Wedbush analyst Robert Driscoll maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and raises the price target from $6 to $8.